7results about How to "Weak immunogenicity" patented technology

The invention relates to a nano antibody G11 for enhancing NK (Natural Killer) cells to kill tumor cells by utilizing ADCC (Adenosine Decarbonyl Cellulose) action and application of the nano antibody G11. The amino acid sequence of the antibody G11 comprises CDR1 shown as SEQ ID No.2, CDR2 shown as SEQ ID No.3 and CDR3 shown as SEQ ID No.4. The invention also relates to a preparation method of the nano antibody G11. The antibody and the CD147 protein have high affinity and specificity, and experiments prove that the antibody can effectively enhance the killing function of NK cells on cells expressing the CD147 protein through antibody-dependent cell-mediated cytotoxic action (ADCC).

The invention relates to an anti-CD147 antibody A5 and application thereof, the anti-CD147 antibody A5 comprises a heavy chain variable region, and the heavy chain variable region comprises a CDR1, a CDR2 and a CDR3; the amino acid sequence of the CDR1 is as shown in SEQ ID NO. 1; the amino acid sequence of the CDR2 is as shown in SEQ ID NO. 2; the amino acid sequence of the CDR3 is as shown in SEQ ID NO. 3. The generic tumor antigen antibody A5 has strong affinity, a chimeric antigen receptor T cell taking the single-domain antibody as an antigen binding domain has strong killing ability to tumor cells, and the antibody can enhance the tumor cell killing ability of NK cells through ADCC effect.

The invention relates to a generic tumor antigen antibody D6 and application thereof, the generic tumor antigen antibody D6 comprises a heavy chain variable region, and the heavy chain variable region comprises CDR1, CDR2 and CDR3; the amino acid sequence of the CDR1 is as shown in SEQ ID NO. 1; the amino acid sequence of the CDR2 is as shown in SEQ ID NO. 2; the amino acid sequence of the CDR3 is as shown in SEQ ID NO. 3. The generic tumor antigen antibody D6 is high in affinity and high in tumor cell killing capacity, and meanwhile the antibody can enhance the tumor cell killing capacity of NK cells through the ADCC effect.

Provided is a vaccine for preventing and / or treating an infection with an influenza virus. The vaccine comprises lipid particles containing a nucleic acid capable of expressing a haemagglutinin (HA) protein of the influenza virus, wherein a lipid is a cationic lipid having general formula (Ia), or a pharmaceutically acceptable salt thereof. [In the formula, R1, R2, p, L1 and L2 are as defined in the specification.]

The application provides an anti-PD-L1 nanobody and a use thereof, and the anti-PD-L1 nanobody comprises at least one VHH fragment, and the VHH fragment comprises three amino acid fragments of CDR1, CDR2 and CDR3. The anti-PD-L1 nanobody and the Fc fusion protein thereof have high specificity and affinity, low immunogenicity to human, and significant anti-tumor effect.

This invention belongs to the field of biomedical technology and relates to a polypeptide targeting cGAS and its applications. The polypeptide comprises an active peptide and a membrane-penetrating peptide, the membrane-penetrating peptide being fused to the N-terminus of the active peptide. The amino acid sequence of the active peptide is identical to amino acid regions 45-63 of human IκB kinase-binding protein (IKIP) or 43-60 of mouse IKIP. The polypeptide provided by this invention can enter cells, specifically bind to cGAS, inhibit cGAS aggregation and phase separation, thereby inhibiting cGAS enzyme activity, reducing type I interferon expression, maintaining antiviral immune homeostasis, and providing a new candidate strategy for the clinical treatment of viral infections and autoimmune diseases.

The present invention relates to a pan-tumor antigen antibody D6 and its application, wherein the pan-tumor antigen antibody D6 comprises a heavy chain variable region, wherein the heavy chain variable region comprises CDR1, CDR2 and CDR3; the amino acid sequence of the CDR1 is shown in SEQ ID NO.1; the amino acid sequence of the CDR2 is shown in SEQ ID NO.2; the amino acid sequence of the CDR3 is shown in SEQ ID NO.3. The pan-tumor antigen antibody D6 of the present invention has strong affinity and strong killing ability to tumor cells, and the antibody can enhance the ability of NK cells to kill tumor cells through ADCC.